SAMR Proposes Guidelines to Curb Commercial Bribery in Pharmaceutical Industry
The State Administration for Market Regulation (SAMR) has unveiled the “Guidelines for Compliance of Pharmaceutical...
Policy / Regulatory
Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027
The People’s Government of Guangdong Province has unveiled an ambitious “Action Plan for Further Promoting...
China’s NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting
The National Medical Products Administration (NMPA) of China has issued a draft proposal for the...
Shanghai Releases Local Guidelines to Correct Unhealthy Practices in Pharmaceutical Procurement and Medical Services
The Shanghai Municipal Health Commission, along with 13 other bureaus, has issued a local adaptation...
NMPA Expands Generic Quality Consistency Evaluation with 83rd Batch of Reference Drugs
The National Medical Products Administration (NMPA) in China has announced the release of the 83rd...
China’s National Healthcare Security Administration Issues Draft Guidelines for Long-Term Care Insurance
The National Healthcare Security Administration (NHSA) has released the “Draft Technical Guidelines for the Preparation...
China’s CDE Releases Draft Guidelines for Biosimilar Drug Labeling
On September 29, 2024, the Center for Drug Evaluation (CDE) of China’s National Medical Products...
Study Predicts 2025 Medicare Part D Negotiation Candidates, With Novo Nordisk’s Semaglutide Leading the List
Researchers in the U.S. have compiled a list of drugs that are anticipated to be...
China Sets New Management Measures for Investigator-Initiated Trials in Medical Institutions
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...
China Unveils Medical Insurance Eligibility Management System for Designated Healthcare Personnel
The National Healthcare Security Administration (NHSA), National Health Commission, and National Medical Products Administration (NMPA)...
Hunan Province Includes Fertility Treatments in Medical Insurance Coverage from October 2024
The Hunan Healthcare Security Administration has issued a notification to include specific assisted reproductive medical...
Shanghai Medical Procurement Platform Sets Price Cap for Non-Locally Supplied Drugs
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) has issued a notification concerning the online procurement prices...
Beijing Authorities Launch Plan to Streamline Temporary Import of Urgently Needed Medical Drugs and Devices
In a joint effort to streamline access to critical medical resources, the Beijing Municipal Medical...
Beijing Expands Medical Insurance Coverage to Include Anti-Aquaporin Antibody Testing and Advanced Heart Procedures
The Beijing Municipal Medical Insurance Bureau and the Beijing Municipal Human Resources and Social Security...
Yunnan Province Increases Pediatric Medical Service Prices for Children Under 6
The Yunnan Provincial Healthcare Security Administration and the Health Commission of Yunnan Province have issued...
Beijing Aims to Establish Rare Disease Drug Security Pilot Zone with ‘White List’ System
Beijing is set to follow in the footsteps of Boao Lecheng with the release of...
Beijing Authorities Release Negative List for Data Export in Key Industries
Authorities in Beijing, including the Beijing Municipal Bureau of Commerce and the Beijing Municipal Service...
China’s NMPA Releases Standards for Brain-Computer Interface Medical Devices
The National Medical Products Administration (NMPA) in China has issued a notification confirming the establishment...
NHSA Concludes 2024 NRDL Review, Announces Submission Deadlines for Drug Manufacturers
The National Healthcare Security Administration (NHSA) has declared the completion of the expert review process...
China Boosts Public Health Subsidies and Targets Weight Management in 2024
The National Health Commission, Ministry of Finance, National Administration of Traditional Chinese Medicine, and National...